Metabolic markers for predicting pathological complete response in neoadjuvant therapy of rectal cancer and applications thereof
By screening for significantly different combinations of metabolic biomarkers using metabolomics technology, a predictive model was constructed, which solved the problem of accurately predicting the probability of pathological complete remission in neoadjuvant therapy for rectal cancer. This enabled the optimization of efficient and accurate treatment plans, improving patient survival rates and quality of life.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- HARBIN METANOTITIA INC
- Filing Date
- 2025-05-16
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies are insufficient to accurately predict the probability of pathological complete response (pCR) in neoadjuvant therapy for rectal cancer, resulting in some patients failing to receive effective treatment and developing radiotherapy resistance, which limits the efficacy and scope of application.
Using metabolomics technology, a group of significantly different metabolic biomarkers was screened by analyzing plasma samples from rectal cancer patients before and after neoadjuvant therapy. Small molecules were separated using liquid chromatography and mass spectrometry, and Lasso regression was used for screening to construct a combination of metabolic biomarkers to predict treatment efficacy.
It enables non-invasive and accurate prediction of the efficacy of neoadjuvant therapy for rectal cancer, helps clinicians optimize treatment plans, improves patient survival rates and quality of life, and promotes the development of personalized and precision treatment for rectal cancer.
Smart Images
Figure CN122409882A_ABST